drugset
drugset / Trial / NCT04566380

ONO-4538 Phase II Rollover Study (ONO-4538-98)

NCT04566380 ↗

Phase 2 Recruiting 59 enrolled Ono Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.

Timeline

Start
2020-09-10
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 240 mg Intravenous
Subject Nivolumab Monoclonal antibody 360 mg Intravenous
Subject Nivolumab Monoclonal antibody 480 mg Intravenous
Background Bevacizumab Monoclonal antibody — Intravenous
Background Capecitabine Small molecule — Oral
Background Oxaliplatin Small molecule — Intravenous
Background S-1 Small molecule — Oral
Background Temozolomide Small molecule — Oral

Indications

No indication recorded.